论文部分内容阅读
目的:探讨增免抑瘤方辅助治疗对晚期卵巢癌术后化疗副反应和患者生存质量的影响。方法:将2009年4月—2012年4月接收的120例处于第Ⅲ~Ⅳ期行卵巢癌细胞减灭术患者。按随机数字表法分为对照组和观察组,每组60例。对照组术后给予紫杉醇联合卡铂化疗6疗程;观察组在对照组基础之上在每次化疗间歇期间给予服用增免抑瘤汤。于化疗前及化疗开始后每3 d检查血、尿、粪便、肝肾功能1次,并且记录胃肠道反应以测定患者毒副反应情况,并通过化疗前及化疗过程中给予卡氏评分(Karnofsky)以及癌症治疗功能系统中卵巢癌子系统(FACT-O)以评价患者生存质量。结果:治疗组在毒副反应发生情况(白细胞、中性粒细胞及血红蛋白降低,肌酐、ALT升高、血尿、恶心呕吐)明显低于照组(P<0.05);生存质量评定结果,卡氏评分:两组化疗前与化疗期间各期卡氏评分均有统计学差异(对照组P<0.05,观察组P<0.01);两组同期卡氏评分比较具有统计学差异(P<0.05)。FACT-O评分:两组化疗前与化疗各期各项评分相比具有统计学差异(P<0.05);两组各期各项功能评分均具有统计学差异(P<0.05)。结论:增免抑瘤方辅助治疗对晚期卵巢癌术后化疗能显著降低化疗副反应并且能改善患者生存质量。
Objective: To investigate the effect of adjuvant chemotherapy and soothing Yifan decoction on postoperative chemotherapy and its quality of life in patients with advanced ovarian cancer. Methods: From April 2009 to April 2012, 120 patients with stage III-IV ovarian cancer cells were treated. According to random number table divided into control group and observation group, 60 cases in each group. The control group was treated with paclitaxel and carboplatin after 6 courses of chemotherapy. The observation group was given Zengqi Yiliu Decoction during the intermittent chemotherapy period on the basis of the control group. The blood, urine, stool, liver and kidney function were examined before chemotherapy and once every 3 days after chemotherapy, and the gastrointestinal reactions were recorded to determine the side effects of the patients. Cardiac scores were obtained before and during chemotherapy Karnofsky) and ovarian cancer sub-system (FACT-O) in the cancer therapy functional system to assess patient quality of life. Results: In the treatment group, the incidence of toxic and side effects (decreased white blood cells, neutrophils and hemoglobin, creatinine, elevated ALT, hematuria and nausea and vomiting) were significantly lower in the treatment group than those in the control group (P <0.05) Score: There was significant difference between the two groups (P <0.05, P <0.01). The Karnofsky scores of the two groups were statistically different (P <0.05). FACT-O score: There was significant difference between the two groups before and after chemotherapy (P <0.05). The functional scores of each group had statistical significance (P <0.05). Conclusion: The adjuvant therapy with ZXILI can significantly reduce the side effects of chemotherapy and improve the quality of life of patients with advanced ovarian cancer after chemotherapy.